Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEHAW Aesther Healthcare Acquisition	$0.00	$0.01	$0.06 ▼ $0.33	N/A	N/A	34,287 shs	N/A
EGLT Egalet	$0.01	$0.24	$0.03 ▼ $1.57	N/A	N/A	853,425 shs	N/A
NEXI NexImmune	$0.00	$0.00	$0.00 ▼ $1.18	N/A	2.04	6,143 shs	N/A
NTHI Neonc Technologies	$5.82 +0.9%	$4.88	$3.20 ▼ $25.00	N/A	N/A	155,841 shs	45,530 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEHAW Aesther Healthcare Acquisition	0.00%	0.00%	+50.00%	-72.14%	-89.97%
EGLT Egalet	0.00%	0.00%	0.00%	0.00%	0.00%
NEXI NexImmune	0.00%	0.00%	+100.00%	+100.00%	-99.98%
NTHI Neonc Technologies	0.00%	+13.67%	+23.83%	-19.39%	+581,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEHAW Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EGLT Egalet	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NEXI NexImmune	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTHI Neonc Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEHAW Aesther Healthcare Acquisition	N/A	N/A	N/A
EGLT Egalet	N/A	N/A	N/A
NEXI NexImmune	N/A	N/A	N/A
NTHI Neonc Technologies	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEHAW Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
EGLT Egalet	N/A	N/A	N/A	N/A	N/A	N/A
NEXI NexImmune	N/A	N/A	N/A	N/A	$3.32 per share	N/A
NTHI Neonc Technologies	$59.99K	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEHAW Aesther Healthcare Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EGLT Egalet	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
NEXI NexImmune	-$32.34M	-$18.54	N/A	∞	N/A	N/A	-534.32%	-213.72%	N/A
NTHI Neonc Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest EGLT, AEHAW, NTHI, and NEXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/18/2025	Q2 2025	NTHI Neonc Technologies	N/A	-$0.30	N/A	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEHAW Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A
EGLT Egalet	N/A	N/A	N/A	N/A	N/A
NEXI NexImmune	N/A	N/A	N/A	N/A	N/A
NTHI Neonc Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEHAW Aesther Healthcare Acquisition	N/A	N/A	N/A
EGLT Egalet	N/A	N/A	N/A
NEXI NexImmune	N/A	0.66	0.66
NTHI Neonc Technologies	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEHAW Aesther Healthcare Acquisition	N/A
EGLT Egalet	19.20%
NEXI NexImmune	9.85%
NTHI Neonc Technologies	N/A

Insider Ownership

Company	Insider Ownership
AEHAW Aesther Healthcare Acquisition	N/A
EGLT Egalet	2.40%
NEXI NexImmune	14.90%
NTHI Neonc Technologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEHAW Aesther Healthcare Acquisition	2	N/A	N/A	Not Optionable
EGLT Egalet	N/A	N/A	N/A	Optionable
NEXI NexImmune	6	1.40 million	1.19 million	Not Optionable
NTHI Neonc Technologies	8	N/A	N/A	N/A

EGLT, AEHAW, NTHI, and NEXI Headlines

Recent News About These Companies

NeOnc Technologies reports Q2 EPS (30c) vs (27c) last year

August 19, 2025 | msn.com

NeOnc Technologies Holdings, Inc.: NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

August 19, 2025 | finanznachrichten.de

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

August 19, 2025 | finance.yahoo.com

New to The Street’s Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

August 14, 2025 | freep.comF

NeOnc Technologies Expands with NuroMENA Holdings Incorporation

August 14, 2025 | msn.com

New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

August 11, 2025 | eagletribune.comE

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

August 11, 2025 | globenewswire.com

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

August 7, 2025 | globenewswire.com

NTHI - NeOnc Technologies Holdings Inc Financials | Morningstar

August 6, 2025 | morningstar.comM

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

August 4, 2025 | globenewswire.com

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

July 30, 2025 | globenewswire.com

NeOnc Technologies Holdings, Inc.: NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment

July 30, 2025 | finanznachrichten.de

NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment

July 30, 2025 | finance.yahoo.com

AI and biotech take on brain cancer

July 30, 2025 | finance.yahoo.com

NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference

July 28, 2025 | tmcnet.com

NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment

July 24, 2025 | finance.yahoo.com

NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on ...

July 24, 2025 | bakersfield.comB

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

July 23, 2025 | globenewswire.com

NeOnc Technologies Secures Board Approval for $50 Million Strategic ...

July 12, 2025 | seekingalpha.com

NeOnc Technologies Holdings, Inc. Secures Board Approval for ... - Nasdaq

July 12, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGLT, AEHAW, NTHI, and NEXI Company Descriptions

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.0039 0.00 (0.00%)

As of 08/15/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

Egalet NASDAQ:EGLT

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.

NexImmune NASDAQ:NEXI

$0.0002 0.00 (0.00%)

As of 08/22/2025

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

Neonc Technologies NASDAQ:NTHI

$5.82 +0.05 (+0.87%)

As of 08/22/2025 04:00 PM Eastern

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time